Recent News

• 02.10.2026 - Phio Announces Safety Monitoring Committee’s (SMC) Positive Wrap-up on Lead Clinical Candidate PH-762 in Skin Cancer Trial
• 01.26.2026 - Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference
• 01.20.2026 - Phio Pharmaceuticals Announces Key Tumor Response Data from all Cohorts in Intratumoral PH-762 Dose Escalation Cutaneous Carcinoma Trial
• 01.15.2026 - Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference January 21-22, 2026
• 12.23.2025 - Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762

Recent Filings

• 02.06.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.06.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.06.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.06.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.06.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.06.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.20.2026 - EX-99.1 EX-99.1
• 01.20.2026 - 8-K Current report
• 01.02.2026 - 4 Statement of changes in beneficial ownership of securities
• 12.29.2025 - 4 Statement of changes in beneficial ownership of securities